These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465 [TBL] [Abstract][Full Text] [Related]
26. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349 [TBL] [Abstract][Full Text] [Related]
27. Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. Goc A; Kochuparambil ST; Al-Husein B; Al-Azayzih A; Mohammad S; Somanath PR BMC Cancer; 2012 Sep; 12():409. PubMed ID: 22974127 [TBL] [Abstract][Full Text] [Related]
28. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C. Li J; Xiang S; Zhang Q; Wu J; Tang Q; Zhou J; Yang L; Chen Z; Hann SS J Exp Clin Cancer Res; 2015 May; 34(1):46. PubMed ID: 25971429 [TBL] [Abstract][Full Text] [Related]
29. Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer. Danquah M; Duke CB; Patil R; Miller DD; Mahato RI Pharm Res; 2012 Aug; 29(8):2079-91. PubMed ID: 22451249 [TBL] [Abstract][Full Text] [Related]
30. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342 [TBL] [Abstract][Full Text] [Related]
31. FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-X Maciel-Silva P; Caldeira I; de Assis Santos I; Carreira ACO; Siqueira FR; Antonioli E; Goldberg AC; Belizário JE; Garay-Malpartida HM BMC Cancer; 2018 Jan; 18(1):90. PubMed ID: 29357840 [TBL] [Abstract][Full Text] [Related]
32. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Butterworth KT; McCarthy HO; Devlin A; Ming L; Robson T; McKeown SR; Worthington J Int J Cancer; 2008 Aug; 123(4):760-8. PubMed ID: 18512241 [TBL] [Abstract][Full Text] [Related]
33. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis. Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738 [TBL] [Abstract][Full Text] [Related]
34. Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models. Bordini J; Morisi F; Elia AR; Santambrogio P; Pagani A; Cucchiara V; Ghia P; Bellone M; Briganti A; Camaschella C; Campanella A Clin Cancer Res; 2020 Dec; 26(23):6387-6398. PubMed ID: 32928793 [TBL] [Abstract][Full Text] [Related]